Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK01 and PD-1 Antibody in Advanced Solid Tumors
NCT07407985Phase 1Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GK01 in solid tumor (advanced stage), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability at 2 years. Started Dec 2025; status: active, not recruiting.
02
Drugs
GK01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07407985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407985.